Agenus Inc
AGEN
查看詳細走勢圖
3.435USD
-0.005-0.15%
交易中 （美東）報價延遲15分鐘
112.72M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-0.15%
5天
-9.37%
1月
-18.60%
6月
-28.14%
今年開始到現在
+25.36%
1年
+21.38%
查看詳細走勢圖
TradingKey Agenus Inc股票評分
單位: USD 更新時間: 2025-12-19操作建議
Agenus Inc當前公司基本面數據相對謹慎，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名131/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價12.33。中期看，股價處於下降通道。近一個月，市場表現非常差，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Agenus Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
3
分析師
買入
評級
12.333
目標均價
+206.04%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Agenus Inc亮點
亮點風險
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
估值低估
公司最新PE估值-2.19，處於3年歷史低位
先鋒集團持倉
明星投資者先鋒集團持倉，最新持倉2.57M股
Agenus Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Agenus Inc簡介
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
公司代碼AGEN
公司Agenus Inc
CEOArmen (Garo H)
網址https://agenusbio.com/
常見問題
Agenus Inc(AGEN)的當前股價是多少？
Agenus Inc(AGEN)的當前股價是 3.435。
Agenus Inc 的股票代碼是什麼？
Agenus Inc的股票代碼是AGEN。
Agenus Inc股票的52週最高點是多少？
Agenus Inc股票的52週最高點是7.340。
Agenus Inc股票的52週最低點是多少？
Agenus Inc股票的52週最低點是1.380。
Agenus Inc的市值是多少？
Agenus Inc的市值是112.72M。
Agenus Inc的淨利潤是多少？
Agenus Inc的淨利潤為-227.43M。
現在Agenus Inc(AGEN)的股票是買入、持有還是賣出？
根據分析師評級，Agenus Inc(AGEN)的總體評級為買入，目標價格為12.333。
Agenus Inc(AGEN)股票的每股收益（EPS TTM）是多少
Agenus Inc(AGEN)股票的每股收益（EPS TTM）是-1.572。
相關品種
+0.65%
+0.21%
-0.87%
-0.02%
+0.37%
+1.21%
+0.52%
-0.95%
-0.26%
+0.59%
-0.45%
-0.09%
+0.06%
-0.08%
+0.37%
+0.71%
+0.88%
0.00%
+0.03%
+1.61%
